Continuous subcutaneous insulin infusion sets may be worn for longer than 3 days.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of DiabetesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Duration of catheter use in patients with diabetes using continuous subcutaneous insulin infusion: A review.Diabetes Technol Ther. 2018; 7: 506-515
- Perceptions and experiences of adult patients with type 1 diabetes using continuous subcutaneous insulin infusion therapy: Results of an online survey.Diabetes Res Clin Pract. 2018; 144: 42-50
- Using insulin infusion sets in CSII for longer than the recommended usage time leads to a high risk for adverse events: Results from a prospective randomized crossover study.J Diabetes Sci Technol. 2015; 9: 1292-1298
- Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy---trouble starts on day 3.J Diabetes Sci Technol. 2010; 4: 976-982
- International survey of insulin pump users: Impact of continuous subcutaneous insulin infusion therapy on glucose control and quality of life.Prim Care Diabetes. 2007; 1: 143-146
- CSII: Longer catheter usage time, a reasonable goal.Diabetes Sci Technol. 2016; 10: 989-990
- Subcutaneous adipose tissue exerts proinflammatory cytokines after minimal trauma in humans.Am J Physiol Endocrinol Metab. 2007; 293: E690-E696
- Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents.J Pediatr. 2008; 152: 622-628
- Nonmetabolic complications of continuous subcutaneous insulin infusion: A patient survey.Diabetes Technol Ther. 2014; 16: 145-149
- Technical risks with subcutaneous insulin infusion.Diabetes Metab. 2006; 32: 279-284
- Prostaglandins, interleukins, and cutaneous inflammation.ImmunoMethods. 1993; 2: 219-226
- Tissue response to subcutaneous infusion catheter.J Diabetes Sci Technol. 2020; 14: 226-232
- Inflammation at site of insulin infusion diminishes glycemic control.J Pharm Sci. 2022; 111: 1952-1961
- A review of the foreign-body response to subcutaneously-implanted devices: The role of macrophages and cytokines in biofouling and fibrosis.J Diabetes Sci Technol. 2008; 2: 768-777
- Phenolic preservative removal from commercial insulin formulations reduces tissue inflammation while maintaining euglycemia.ACS Pharmacol Transl Sci. 2021; 4: 1161-1174
- Localized and targeted delivery of NSAIDs for treatment of inflammation: A review.Exp Bio Med (Maywood). 2019; 244: 433-444
- Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat.J Pharmacol Exp Ther. 1999; 288: 288-297
- Biological variation of measured and estimated glomerular filtration rate in patients with chronic kidney disease.Kidney Int. 2019; 96: 429-435
- A prospective study of insulin infusion set use for up to 7 days: Early replacement reasons and impact on glycemic control.Diabetes Technol Ther. 2020; 22: 734-741
Article info
Publication history
Published online: August 06, 2022
Accepted:
July 29,
2022
Received in revised form:
July 22,
2022
Received:
January 21,
2022
Identification
Copyright
© 2022 Canadian Diabetes Association.
